Bitar Sara Mona, Moussa Maen
Department of Gastroenterology, Faculty of Medicine, University of Aleppo, Syria.
Ann Med Surg (Lond). 2022 Jan 15;74:103252. doi: 10.1016/j.amsu.2022.103252. eCollection 2022 Feb.
Upper gastrointestinal bleeding (UGIB) is a life-threatening medical emergency characterized by bleeding from the esophagus, stomach, or duodenum. This study aims to analyze the risk factors for upper gastrointestinal tract rebleeding among acute peptic ulcer patients.
This is a cohort clinical study conducted between July 2018 and June 2020. Patients admitted or hospitalized because of UGIB or developed it during their hospital stay were included.s The patients were divided into two groups for the statistical analysis using Forrest's ulcer rebleeding risk classification. Group 1: Forrest 1a+1b+2a+2b, and group 2: Forrest 2c+3. The fasting time before the endoscopic procedure was from 12 to 24 hours. Follow-ups were conducted for 30 days after the treatment.
The total number of included subjects was 152, out of which 57.89% (n = 88) were male patients. The mean SD for patients' age was 52.63 16.89±; more than 40% (n = 62) of subjects were using antiplatelet medications, while only 13.15% (n = 20) used NSAIDs, and the mean SD for the transferred units was 2.32 ± 1.88, 7.24% (n = 11) of patients died. After 30 days of the treatment, 6.57% (n = 10) of patients suffered from recurrent bleeding. The most common presentation was melena 67.95% (n = 103), 53% (n = 81) of patients had hematemesis, 69.73% (n = 106) patients had gastric ulcer and 30.26% (n = 46) had duodenal ulcers.
Age, NSAIDs, altered mental capacity, Forrest classification (Ia,Ib, and IIa), and blood transfusion were associated with a higher risk of rebleeding. Furthermore, patients who needed 3.83 blood units were at higher risk of recurrent bleeding.
上消化道出血(UGIB)是一种危及生命的医疗急症,其特征为食管、胃或十二指肠出血。本研究旨在分析急性消化性溃疡患者上消化道再出血的危险因素。
这是一项于2018年7月至2020年6月期间开展的队列临床研究。纳入因UGIB入院或住院期间发生UGIB的患者。采用福里斯特溃疡再出血风险分类法将患者分为两组进行统计分析。第1组:福里斯特1a+1b+2a+2b,第2组:福里斯特2c+3。内镜检查前禁食时间为12至24小时。治疗后进行30天随访。
纳入的受试者总数为152例,其中男性患者占57.89%(n = 88)。患者年龄的平均标准差为52.63±16.89;超过40%(n = 62)的受试者正在使用抗血小板药物,而仅13.15%(n = 20)使用非甾体抗炎药(NSAIDs),转科次数的平均标准差为2.32±1.88,7.24%(n = 11)的患者死亡。治疗30天后,6.57%(n = 10)的患者出现复发性出血。最常见的表现是黑便,占67.95%(n = 103),53%(n = 81)的患者有呕血,69.73%(n = 106)的患者有胃溃疡,30.26%(n = 46)有十二指肠溃疡。
年龄、非甾体抗炎药、精神状态改变、福里斯特分类(Ia、Ib和IIa)以及输血与再出血风险较高相关。此外,需要3.83个单位血液的患者复发性出血风险较高。